REG - IXICO plc - Trading Update

IXICOAnnouncement

Today 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250717:nRSQ3611Ra&default-theme=true

RNS Number : 3611R  IXICO plc  17 July 2025

IXICO plc

("IXICO", the "Company" or the "Group")

 

Revenues anticipated to be ahead of expectations for the year ending 30
September 2025

 

 

17 July 2025 IXICO plc (AIM: IXI) - London, UK. IXICO, a global leader in
neuroscience imaging and biomarker analytics, using its AI-driven platform to
help advance drug development in neurological disorders, today provides a
trading update for the financial year ending 30 September 2025.

 

The Company anticipates revenues to be at least £6.3 million, ahead of
expectations and representing a 9% increase on 2024 revenues, thereby
solidifying its stated return to growth.  Further, it is expected that this
revenue growth will continue into 2026, moving the Company towards medium term
profitability.

 

IXICO has seen positive sales momentum driven by the implementation of the
Company's 'Innovate Lead Scale' strategy, which has seen IXICO deliver
scientific innovation while expanding commercial and geographic reach in key
therapeutic areas and new market verticals.  As indicated in the Half-year
Trading Update on 16 April 2025, the Company has therefore increased the
expected investment in 2025 to drive revenue growth in 2026 and beyond.

 

The Company expects to hold cash of at least £3.0 million at the end of the
financial year.

 

Final results for the year ending 30 September 2025 will be announced in
December 2025.

 

Bram Goorden, CEO of IXICO, said: "The Innovate Lead Scale strategy outlined
during our capital raise has begun to deliver results.  The positive momentum
is a result of a team approach, executing with discipline to grow revenues,
expand market share and diversify the neurological therapeutic areas we
operate in. In addition, we are rapidly advancing our technology platform
offering with new differentiated biomarker analytics products and applications
fit for scale. This activity strengthens my belief that we will continue to
build upon this year's commercial success and the progress we are making
towards profitability in the medium term".

Ends

 

The information contained within this announcement is deemed by the Company to
constitute inside information as stipulated under the UK version of the EU
Market Abuse Regulation 596/2014 which is part of UK law by virtue of the
European Union (Withdrawal) Act 2018, as amended and supplemented from time to
time. Upon the publication of this announcement, this inside information is
now considered to be in the public domain.

 

 

For further information please contact:

 

 IXICO plc                                   +44 (0) 20 3763 7499
 Grant Nash, Chief Financial Officer

 James Chandler, Chief Business Officer

 Cavendish Capital Markets Limited           +44 (0) 20 7220 0500

 (Nominated Adviser and Sole Broker)
 Giles Balleny (Corporate Finance)

 Nigel Birks (Healthcare Specialist Sales)

 Harriet Ward (Corporate Broking)

 Michael F Johnson (Sales)

 

 

About IXICO www.IXICO.com (http://www.IXICO.com)

IXICO is a global leader in neuroscience imaging and biomarker analytics,
using its proprietary AI-driven platform to help advance the treatment of
neurological disorders and reduce the uncertainties associated with drug
discovery, development and monitoring.   As a key part of the global
neurological disease research community, the Company has built a global
reputation and 20-year track record as an end-to-end Imaging Contract Research
Organisation (iCRO) working with leading pharma companies, innovative
biotech's, disease consortia and non-profit organisations. IXICO has supported
hundreds of neurological clinical trials, analysed hundreds of thousands scans
and built an expansive network of expert imaging centres around the world.

 

The IXICO Platform is tailor-made for neurological disease, reliably
processing data from global trials, precisely measuring key imaging biomarkers
associated with the identification, progression and treatment of diseases such
as Alzheimer's, Huntington's and Parkinson's.  Image data is interrogated by
the Platform and IXICO's expert scientists translating complex data into
clinically meaningful while minimizing data variability and increasing
reproducibility.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  TSTSFIFIMEISEDW